Website: https://www.syneoshealth.com/
Syneos Health® is the only fully integrated biopharmaceutical solutions organization purpose-built to accelerate customer success. The firm leads with a product development mindset, strategically blending clinical development, medical affairs, and commercial capabilities to address modern market realities.
Biopharmaceutical Acceleration Model
Syneos Health is the only company in the biopharmaceutical services industry purpose-built to create tremendous success for its customers. At Syneos Health, clinical and commercial live under the same roof and constantly share real-world knowledge and insights that lead to getting the job done better, smarter, and faster.
Syneos Health calls this new way of collaborative working the Biopharmaceutical Acceleration Model or BAM™.
How does it work? BAM is an end-to-end concept, working across Syneos Health’s clinical and commercial capabilities and driven by each and every one of its approximately 28,000 employees. Importantly, it also incorporates many unique Syneos Health disciplines including the Trusted Process®, Syneos One®, the Syneos Health Data Lake Ecosystem, Real World Evidence, and its deep therapeutic expertise — each providing a constant stream of insights focused on two critical areas: patient behavior and process acceleration.
These insights, along with unique approaches to data and digital, which we call Dynamic Assembly®, allow the organization not only to solve problems, but also solve them more quickly, increasing the likelihood of regulatory approval and maximizing commercial success. Syneos Health believes that BAM is the future of biopharmaceutical development. And more importantly, it is the key to shortening the distance from lab to life for its customers.
Solutions
Clinical Development
Every customer has unique clinical development needs. Our fit-for-purpose CRO solutions are tailored to your product and requirements. Whatever your needs, we can adopt new processes and technologies, diverse therapeutic expertise, and access to commercial insights that can facilitate shorter and more efficient trials designed to improve the likelihood of regulatory and commercial success.
Commercialization
At Syneos Health®, we are able to enhance brand performance by leveraging data and insights, accumulated best practices, and deep access to therapeutic expertise. Serving customers of all sizes, our CCO (Contract Commercial Organization) capabilities are the broadest and most robust in the industry delivering flexible, targeted, multi-channel programs designed to produce a higher likelihood of launch success. At the same time, our commercial and market insights along with proprietary data access can improve clinical trial design and accelerate patient recruitment. It’s a powerful platform for the modern biopharmaceutical world.
Consulting
Built on the combination of Campbell Alliance and Kinapse, Syneos Health Consulting is a leading management and consulting firm specializing in the life sciences industry. We provide deep subject matter expertise over the entire lifecycle of an organization, portfolio, or asset, and our unique ability to leverage end-to-end capabilities and global functional and therapeutic experts results in highly customized solutions. Deep pre- and post-launch expertise generates strategic insights that yield implementation-focused recommendations designed to reduce risk, speed time to market, and increase overall asset and portfolio value.
Trusted Process Guiding Product Development
The Trusted Process is Syneos Health’s proprietary, metrics-driven methodology initially developed to manage all aspects of clinical studies. This unique, four-step approach delivers faster results while maintaining data integrity and reducing operational risk and variability.
· Average study starts up-time four weeks faster than industry average
· Patient enrolment completed as planned
· Database lock faster than industry average
Syneos Health® is also applying the Trusted Process to Commercial Solutions to drive greater operating efficiencies and improved times to market.
PlanActivation®
Once we receive your request for a proposal, our therapeutic experts create a customized study delivery plan. Combining quality with a robust feasibility evaluation, we develop a solid strategy to deliver your protocol.
QuickStart®
We begin the selected services with our best-in-class project management methodologies. Experienced project teams turn strategy into comprehensive plans, focusing on your priorities. We meet with you at a week-long camp to review all aspects of the project, where we agree on goals, establish study ownership and clarify responsibilities. This reduces cycle times and the potential for future strategy revisions. At the end of the week, everyone has the same vision and has agreed to a plan that covers project milestones, deliverables, key risks, and response plans.
ProgramAccelerate®
This is the point at which study sites are activated and begin contributing to enrollment and data generation. The project team focuses on delivery by overseeing the project activities and managing risks. The project’s performance is monitored to resolve issues immediately and keep you informed.
QualityFinish®
As soon as the first enrolled patient completes the study, we begin the next phase of intense planning. We reassemble the project management team to review the deliverables and evaluate project performance. This unique approach reduces operational risk, variability, and cycle times.
The Leadership
Michelle Keefe, Chief Executive Officer
Michelle has 30+ years of life sciences expertise and a proven track record of creating cross-collaborative, agile teams that accelerate product development success. Most recently, Michelle served as Syneos Health’s President of Medical Affairs and Commercial Solutions, where she drove the transformation of the Company’s Commercial business.
Her successes across the product development continuum include launching Kinetic™, Syneos Health’s modern customer engagement capability; building integrated solutions such as Full-Service Commercial and Medical Affairs; and collaborating to drive growth in Syneos One, the Company’s unique end-to-end offering.
She has also spent 20 years at Pfizer, with increasing levels of responsibility culminating as a Regional President and led market development for the Visiting Nurse Service of NY. Prior to that, she served as Global Group President and Chief Development Officer at Publicis Health, overseeing the Contract Sales Organization, medical affairs, and specialty agency functions.
She is the Executive sponsor of the Syneos Health DE&I Council and sits on the Healthcare Businesswomen’s Association’s (HBA) Global Board of Directors.
“Syneos Health fully expresses our value proposition – that is, our ability to deliver integrated end-to-end solutions and create new paths for our customers to develop and commercialize their therapies.”
